Leadership & Pay ·
Neurocrine Biosciences appoints Eiry W. Roberts as CMO with $1.25M equity grant
NBIXNeurocrine Biosciences Inc
Neurocrine Biosciences announced that Sanjay Keswani, M.D., will depart as Chief Medical Officer effective September 25, 2026, following a mutual agreement with the Board. Eiry W. Roberts, M.D., has been appointed to succeed him, effective September 28, 2026. Dr. Roberts’ compensation package includes an annual base salary of $825,000 and a target cash incentive bonus equal to 60% of her base pay. Her equity grants total approximately $1.25 million, comprising stock options ($625,000), restricted stock units ($250,000), and performance-vesting restricted stock units ($375,000). Dr. Keswani is entitled to severance benefits under the Company’s Executive Severance Plan. Neurocrine Biosciences operates in the biotechnology industry, focusing on the discovery and development of therapies for neurological and endocrine disorders.